Memory and attention impairment in middle-aged patients: diagnosis and treatment


  • T.I. Nasonova Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • T.V. Kolosova Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • T.M. Slobodyn Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • O.V. Klymenko Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • I.V. Kurochkin Kyiv Municipal Clinical Hospital 9, Kyiv, Ukraine
  • T.M. Riabychenko Kyiv Municipal Clinical Hospital 9, Kyiv, Ukraine
  • O.V. Tyshkevych Kyiv Municipal Clinical Hospital 9, Kyiv, Ukraine
  • Yu.A. Buhaiov Kyiv Municipal Clinical Hospital 9, Kyiv, Ukraine
  • Yu.I. Holovchenko Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine



stress, psychoemotional disorders, cognitive impairment, treatment


Background. Cognitive and psychoemotional disorders in middle-aged patients are an important medical and social problem. Diagnosis and treatment of violations in cognitive and emotional sphere is an urgent task of family doctors, therapists, neurologists, psychiatrists, etc. The role of chronic psychosocial stress, which is closely linked to the pathophysiology of depressive and anxiety disorders, plays an important role in the impairment of memory, neurodynamic functions in middle-aged people. Attention, processing speed and the ability to switch from one activity to another are impaired, patients complain of slowing thinking and reactions that often interfere with their professional activity. Search for medicines that reduce anxiety and do not impair cognitive function and vegetative state is relevant. The preliminary results of experimental studies of choline alphoscerate demonstrated its ability to reduce age-related structural changes in the frontal cortex of the brain and the hippocampus. Objective: diagnosis of cognitive dysfunction associated with psychoemotional disorders in middle-aged patients and treatment of cognitive and emotional disorders with the addition of Reneuro Plus dietary supplement. Materials and methods. Sixty patients aged 44 to 59 years with mild to moderate cognitive impairment were screened. The psychodiagnostic study was performed using: Luria test, Montreal Cognitive Assessment tool, digit symbol substitution test, Spielberger-Khanin personal and reactive anxiety scales. Treatment included antihypertensive, metabolic, hypolipidemic therapy. In addition, the patients in the main group (n = 30) were additionally receiving Reneuro Plus dietary supplement. Results. Cognitive impairment was observed in the following areas: attention and concentration, memory, optical and spatial skills, abstract thinking and counting. After treatment, almost all patients in group 1 noted improvement in both mood and cognitive function: mental performance increased, memory improved, number of episodes of forgetfulness and inattention decreased, concentration of attention increased, while in the group 2, the number of patients with significant improvement was significantly lower (p < 0.05). The results of reactive anxiety testing showed a decrease in the scores for this scale in Reneuro Plus group. The difference between the data before and after treatment in the main group was statistically significant (p < 0.05). The tolerability of Reneuro Plus dietary supplement was evaluated as good, there were no cases of drug withdrawal. Laboratory studies did not have a negative effect on the blood, renal and liver function. The treatment of psychoemotional disorders with cognitive impairment requires considerable attention of the clinician. When cognitive impairment is associated with anxiety and depression, therapy should be started from the treatment of anxiety and depression, as cognitive disorders in this case may be secondary to emotional disorders. It should be borne in mind that many drugs, in particular cholinolytics, tricyclic antidepressants, neuroleptics, benzodiazepines, may worsen cognitive functions. Conclusions. In middle-aged patients, on the background of chronic stress, psychoemotional disorders with cognitive impairment are formed. The use of Reneuro Plus dietary supplement in the comprehensive treatment of cognitive impairment associated with anxiety disorders contributes to the improvement of cognitive and psychoemotional functions in middle-aged patients. The 30-day course of therapy using Reneuro Plus dietary supplement is safe and does not cause unwanted side effects.


Алфимова М.В. Влияние тревоги на когнитивные процессы при депрессивном синдроме / М.В. Алфимова, И.А. Лапин, Е.В. Аксенова, Т.С. Мельникова // Социальная и клиническая психиатрия. — 2017. — Т. 27, № 1. — С. 5-12.

Антоненко Л.М. Когнитивные и эмоциональные нарушения в среднем возрасте: вопросы диагностики и лечения /

Л.М. Антоненко, В.А. Парфенов // Медицинский совет. — 2015. — № 10. — С. 22-27.

Бурчинський С.Г. Комплексная коррекция тревожных и когнитивных расстройств в ангионеврологии: цели, задачи, инструменты // Міжнародний неврологічний журнал. — 2017. — № 8(94). — С. 73-78.

Выговская С.Н. Хроническая ишемия головного мозга — от правильной диагностики к адекватной терапии / Выговская С.Н., Нувахова М.Б., Дорогинина А.Ю., Рачин А.П. // РМЖ. — 2015. — № 12. — С. 694. — Режим доступу:

Громова Д.О. Когнитивные нарушения у больных молодого и среднего возраста: диагностика и подходы к терапии / Д.О. Громова Н.В. Вахнина // Эффективная фармакотерапия. Неврология. — 2017. — № 3(31).

Насонова Т.І. Нейровегетативні та когнітивні порушення, асоційовані з тривогою у пацієнтів середнього віку із цереброваскулярними захворюваннями / Т.І. Насонова, О.В. Кліменко, Т.В. Колосова, Г.В. Горєва, Ю.І. Головченко, О.В. Тишкевич, О.М. Гурмак // Семейная медицина. — 2017. — № 2. — С. 97-102. — Режим доступу:

Филатова Е.Г. Терапия нарушений памяти и внимания у молодых пациентов / Е.Г. Филатова, М.В. Наприенко // Неврология, нейропсихиатрия, психосоматика. — 2013. — 3. — 18-23.



Original Researches